Good MorningThe equities market started the week with a whimper. The S&P 500 gained less than a tenth of a percentage point at the high of the day but did set a new all-time high record. The move comes just days before the peak of the S&P 500 earnings reporting season and is a sign of high expectation regarding the results. The risk for the market now is that Q1 growth is already priced into stocks which is a situation that could lead to a sell-off.
This week’s earnings reports come from a broad array of sectors but the focus will be on the financials. The financials are the new bellwethers and will set the tone for the season. Topping the list of names are J.P. Morgan Chase, Goldman Sachs, Morgan Stanley, Bank of America, and Citigroup. Also of note will be earnings reports from transportation leader J.B. Hunt, consumer staples giant Pepsico, and Alcoa.
Featured: Former U.S. Congressman—here’s how rich get richer (Stansberry (Affiliate)) 
|
Markets | | | Pandemic lockdowns boosting business among digital sales platforms. By now, we’re all familiar with the theme of pandemic lockdowns boosting business among digital sales platforms, such as Shopify (NYSE: SHOP), Etsy (NASDAQ: ETSY), and Fiverr (NYSE: FVRR). Read the Full Story |
|
|
Tech | | | Asian shares were mostly higher on Tuesday with hopes growing for a global economic rebound despite surging coronavirus cases in many places.
China reported its exports rose nearly 31% in March, in line with expectations but weaker than the 60% growth seen in the first two months of ... Read the Full Story |
|
Markets | | | Global shares were mostly higher on Tuesday with hopes growing for a global economic rebound despite surging coronavirus cases in many places.
France's CAC 40 gained 0.3% in early trading to 6,181.52, while Germany's DAX edged up 0.2% to 15,251.55. Britain's FTSE 100 fell less than 0... Read the Full Story |
|
From Our PartnersChris Rowe says there's a huge stock market event looming - and he's revealing his #1 pick for free. | | Click here to find out more. |
|
Stocks | | |
Concrete and aggregate products maker U.S. Concrete (NASDAQ: USCR) stock has been on a tear thanks to the housing boom and tailwinds created by the Biden infrastructure bill. The stock has benefited as both a pandemic benefactor from housing and re-opening play with infrastructure spending. Constr... Read the Full Story |
|
Politics | | | India said Tuesday that it will approve the use of all coronavirus vaccines that have been given an emergency nod by the World Health Organization or regulators in the United States, Europe, Britain or Japan.
India’s Health Ministry said the decision was aimed at hastening the use of ... Read the Full Story |
|
|
Markets | | | The U.K. economy grew 0.4% in February, rebounding from a sharp drop the previous month, as the rapid rollout of COVID-19 vaccines boosted confidence in a recovery from the pandemic.
The Office for National Statistics said Tuesday that the expansion was led by a 1.3% increase in manuf... Read the Full Story |
|
Politics | | | The Australian government said Tuesday it had decided against buying the single-dose Johnson & Johnson coronavirus vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot.
The government had been in talks with the New Jersey-based pharmaceut... Read the Full Story |
|
Markets | | | E-commerce and auction platform eBay (NASDAQ: EBAY) shares are forming a perfect storm breakout powered by the acceleration of collectibles market arguably fueled in part by stimulus checks and economic recovery. Read the Full Story |
|
Markets | | | Sometimes, you have a company like Uber (NYSE:UBER) that comes along and creates an innovative product or service which makes it difficult to imagine what life was like before it. If you aren’t familiar with this company, Uber provides a ridesharing application that offers a quick and convenie... Read the Full Story |
|
Markets | | | The market is as highly valued as we've ever seen it and ripe for a correction. In our view, it's only a matter of timing, depth, and duration. If the Q1 reporting season fails to impress and not just with Q1 results the timing could be sooner rather than later. Read the Full Story |
|
The Early Bird Stock Of The Day Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. | | View Today's Stock Pick |
|
